Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes

Diabetes Care ◽

10.2337/dc20-2080 ◽

2020 ◽

pp. dc202080

Author(s):

Francesco Zaccardi ◽

David E. Kloecker ◽

John B. Buse ◽

Chantal Mathieu ◽

Kamlesh Khunti ◽

...

Keyword(s):

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Effects ◽

Cardiovascular Outcome ◽

Glucose Lowering ◽

Cardiovascular Outcome Trials

Download Full-text

Comparison of New Glucose-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes: A Network Meta-Analysis of Cardiovascular Outcome Trials

SSRN Electronic Journal ◽

10.2139/ssrn.3436269 ◽

2019 ◽

Author(s):

Caroline K. Kramer ◽

Chang Ye ◽

Ravi Retnakaran

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Secondary Prevention ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Primary And Secondary Prevention ◽

Glucose Lowering ◽

Cardiovascular Outcome Trials ◽

Prevention Of Cardiovascular Disease

Download Full-text

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(20)30038-3 ◽

2020 ◽

Vol 8 (5) ◽

pp. 418-435 ◽

Cited By ~ 19

Author(s):

Olivia R Ghosh-Swaby ◽

Shaun G Goodman ◽

Lawrence A Leiter ◽

Alice Cheng ◽

Kim A Connelly ◽

...

Keyword(s):

Heart Failure ◽

Systematic Review ◽

Type 2 Diabetes ◽

At Risk ◽

Cardiovascular Events ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Glucose Lowering ◽

Cardiovascular Outcome Trials

Download Full-text

Faculty Opinions recommendation of SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734434782.793555944 ◽

2019 ◽

Author(s):

Wilbert Aronow

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Secondary Prevention ◽

Meta Analysis ◽

Sglt2 Inhibitors ◽

Cardiovascular Outcome ◽

Primary And Secondary Prevention ◽

Cardiovascular Outcome Trials ◽

Renal Outcomes

Download Full-text

Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A Meta-analysis of Cardiovascular Outcome Trials

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2021.108648 ◽

2021 ◽

pp. 108648

Author(s):

Awadhesh Kumar Singh ◽

Ritu Singh

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Meta Analysis ◽

Cardiovascular Outcomes ◽

Cardiovascular Outcome ◽

Cardiovascular Outcome Trials

Download Full-text

Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis

Cardiovascular Diabetology ◽

10.1186/s12933-020-01067-8 ◽

2020 ◽

Vol 19 (1) ◽

Cited By ~ 5

Author(s):

Marco Castellana ◽

Filippo Procino ◽

Rodolfo Sardone ◽

Pierpaolo Trimboli ◽

Gianluigi Giannelli

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Cardiovascular Outcome Trials

Download Full-text

Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions

Practical Diabetes ◽

10.1002/pdi.1976 ◽

2015 ◽

Vol 32 (8) ◽

pp. 301-304

Author(s):

Jyothis T George

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Outcome ◽

Glucose Lowering ◽

Cardiovascular Outcome Trials

Download Full-text

Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2019.04.003 ◽

2019 ◽

Vol 43 (7) ◽

pp. 538-545.e2 ◽

Cited By ~ 4

Author(s):

Osamah M. Alfayez ◽

Abdulaali R. Almutairi ◽

Ali Aldosari ◽

Majed S. Al Yami

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Cardiovascular Safety ◽

Cardiovascular Outcome Trials

Download Full-text

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus

Clinical Therapeutics ◽

10.1016/j.clinthera.2016.04.037 ◽

2016 ◽

Vol 38 (6) ◽

pp. 1288-1298 ◽

Cited By ~ 21

Author(s):

Guntram Schernthaner ◽

Marie Helene Schernthaner-Reiter ◽

Gerit-Holger Schernthaner

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Treatment Strategies ◽

Cardiovascular Outcome ◽

Glucose Lowering ◽

Cardiovascular Outcome Trials ◽

Future Treatment

Download Full-text

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes

The Lancet ◽

10.1016/s0140-6736(14)61672-x ◽

2014 ◽

Vol 384 (9948) ◽

pp. 1096

Author(s):

Olga Vaccaro ◽

Maria Masulli ◽

Enzo Bonora ◽

Stefano Del Prato ◽

Gabriele Riccardi

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Outcome ◽

Glucose Lowering ◽

Cardiovascular Outcome Trials

Download Full-text

Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials

Diabetes & Metabolic Syndrome Clinical Research & Reviews ◽

10.1016/j.dsx.2020.04.051 ◽

2020 ◽

Vol 14 (4) ◽

pp. 715-722

Author(s):

Awadhesh Kumar Singh ◽

Ritu Singh

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Meta Analysis ◽

Cardiovascular Outcomes ◽

Cardiovascular Outcome ◽

Cardiovascular Outcome Trials

Download Full-text